Theseus Pharmaceuticals Inc (THRX)

[surf1944]

8:05AM Theravance Announces Reintroduction of VIBATIV (telavancin) to the U.S. Market (THRX) 36.80 : Co announces that it has commenced shipments of VIBATIV (telavancin) into the US wholesaler channel. VIBATIV is approved in the US for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus when alternative treatments are not suitable, and for the treatment of complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of Gram-positive bacteria, including Staphylococcus aureus, both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains.